Spyre Therapeutics, Inc. SYRE Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s pre-tax income?
- Spyre Therapeutics, Inc. (SYRE) reported pre-tax income of -$69.01M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s pre-tax income changed year-over-year?
- Spyre Therapeutics, Inc.'s pre-tax income decreased by 54.1% year-over-year, from -$44.79M to -$69.01M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s pre-tax income?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s pre-tax income has grown at a 24.0% compound annual growth rate (CAGR), from -$65.66M to -$155.22M.
- What does pre-tax income mean?
- The company's total profit or loss before paying income taxes.
- How do you interpret pre-tax income?
- A positive value indicates overall profitability, while a negative value indicates a net loss for the period.
- How does pre-tax income compare across companies?
- Standard financial reporting metric used to compare performance across different tax jurisdictions.